摘要
目的评价胱天蛋白酶3(caspase-3)活性作为乳腺癌新辅助化疗(neoadjuvant chemotherapy,NAC)临床反应预测指标的功能。方法 25例接受NAC治疗的乳腺癌患者用于本回顾性研究。采用分光光度法检测治疗前活检标本及治疗后手术切除标本caspase-3活性。结果治疗后caspase-3活性提高,提高的caspase-3活性与较佳的临床应答有关。结论NAC治疗影响caspase-3活性,caspase-3活性可能指示NAC疗效。
Objective To evaluate the role of caspase-3 activity as a predictor of clinical response after neoadjuvant chemotherapy（NAC） for breast cancer. Methods A total of 25 patients with breast cancer receiving NAC were retrospectively studied.Caspase-3 activity in pre-treatment biopsies and post-treatment surgical samples was assessed by a spectrometric method. Results Caspase-3 activity was increased after treatment.The improved caspase-3 activity was associated with better clinical response. Conclusion NAC treatment can affect caspase-3 activity,and caspase-3 activity may predict the therapeutic effect of NAC.
出处
《华南国防医学杂志》
CAS
2012年第6期545-546,595,共3页
Military Medical Journal of South China
基金
973计划前期研究专项课题(2010CB535002)
湛江市科技计划项目(2012C030202)
关键词
胱天蛋白酶3活性
新辅助化疗
乳腺癌
Caspase-3 activity
Neoadjuvant chemotherapy
Breast cancer
